[go: up one dir, main page]

SG11202113221RA - Anti-cd137l antibodies and methods of using same - Google Patents

Anti-cd137l antibodies and methods of using same

Info

Publication number
SG11202113221RA
SG11202113221RA SG11202113221RA SG11202113221RA SG11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA
Authority
SG
Singapore
Prior art keywords
cd137l
antibodies
methods
same
cd137l antibodies
Prior art date
Application number
SG11202113221RA
Inventor
Fangyong Du
Guizhong Liu
Peter Peizhi Luo
Original Assignee
Adagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Pte Ltd filed Critical Adagene Pte Ltd
Publication of SG11202113221RA publication Critical patent/SG11202113221RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202113221RA 2019-06-05 2020-06-04 Anti-cd137l antibodies and methods of using same SG11202113221RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019090091 2019-06-05
PCT/CN2020/094371 WO2020244574A1 (en) 2019-06-05 2020-06-04 Anti-cd137l antibodies and methods of using same

Publications (1)

Publication Number Publication Date
SG11202113221RA true SG11202113221RA (en) 2021-12-30

Family

ID=73652442

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113221RA SG11202113221RA (en) 2019-06-05 2020-06-04 Anti-cd137l antibodies and methods of using same

Country Status (8)

Country Link
US (1) US20220089757A1 (en)
EP (1) EP3980461A1 (en)
JP (1) JP2022535538A (en)
CN (1) CN114450305A (en)
AU (1) AU2020287181A1 (en)
CA (1) CA3139968A1 (en)
SG (1) SG11202113221RA (en)
WO (1) WO2020244574A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2015094123A1 (en) * 2013-12-20 2015-06-25 National University Of Singapore Differentiation therapy with cd137 ligand agonists
EP3394107A1 (en) * 2015-12-22 2018-10-31 AbbVie Stemcentrx LLC Novel anti-tnfsf9 antibodies and methods of use
EP3423078A4 (en) * 2016-03-03 2019-11-06 Cue Biopharma, Inc. T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE
CA3059366A1 (en) * 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
KR20180119135A (en) * 2017-04-24 2018-11-01 주식회사 제넥신 4-1bbl variant and fused protein comprising same
WO2019036855A1 (en) * 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE

Also Published As

Publication number Publication date
CA3139968A1 (en) 2020-12-10
CN114450305A (en) 2022-05-06
JP2022535538A (en) 2022-08-09
AU2020287181A1 (en) 2022-01-20
WO2020244574A1 (en) 2020-12-10
EP3980461A1 (en) 2022-04-13
US20220089757A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
EP4031177A4 (en) Anti-tnfr2 antibodies and methods of use
IL280225A (en) Novel cd47 antibodies and methods of using same
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and their methods of use
IL277212A (en) Anti-klk5 antibodies and methods of use
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL288886A (en) Antibodies and methods of use
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof
HK40105211A (en) Anti-ly6g6d antibodies and methods of use
HK40082835A (en) Anti-ly6g6d antibodies and methods of use
HK40081755A (en) Anti-ror-2 antibodies and methods of use
HK40066875A (en) Antibodies and methods of use
HK40070022A (en) Anti-mertk antibodies and their methods of use